Literature DB >> 26705339

CD30-targeting drugs: cure for mastocytosis?

Irina Maric1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26705339      PMCID： PMC4692137          DOI： 10.1182/blood-2015-11-678631

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.

Authors:  Karl Sotlar; Sabine Cerny-Reiterer; Karina Petat-Dutter; Harald Hessel; Sabina Berezowska; Leonhard Müllauer; Peter Valent; Hans-Peter Horny
Journal:  Mod Pathol       Date:  2010-12-24       Impact factor: 7.842

2.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

4.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Authors:  Jason Gotlib; Caroline Berubé; Joseph D Growney; Ching-Cheng Chen; Tracy I George; Christopher Williams; Tomohiro Kajiguchi; Jia Ruan; Stan L Lilleberg; Jeffrey A Durocher; Jack H Lichy; Yanfeng Wang; Pamela S Cohen; Daniel A Arber; Michael C Heinrich; Len Neckers; Stephen J Galli; D Gary Gilliland; Steven E Coutré
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

6.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

7.  Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Authors:  Nicole M Okeley; Jamie B Miyamoto; Xinqun Zhang; Russell J Sanderson; Dennis R Benjamin; Eric L Sievers; Peter D Senter; Stephen C Alley
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

Review 8.  Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.

Authors:  Ashley M Newland; Jenny X Li; Lindsey E Wasco; May T Aziz; Denise K Lowe
Journal:  Pharmacotherapy       Date:  2013-01       Impact factor: 4.705

9.  Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Authors:  Katharina Blatt; Sabine Cerny-Reiterer; Juliana Schwaab; Karl Sotlar; Gregor Eisenwort; Gabriele Stefanzl; Gregor Hoermann; Matthias Mayerhofer; Mathias Schneeweiss; Sylvia Knapp; Thomas Rülicke; Emir Hadzijusufovic; Karin Bauer; Dubravka Smiljkovic; Michael Willmann; Andreas Reiter; Hans-Peter Horny; Peter Valent
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

10.  Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.

Authors:  Michinori Ogura; Kensei Tobinai; Kiyohiko Hatake; Kenichi Ishizawa; Naokuni Uike; Toshiki Uchida; Tatsuya Suzuki; Tomohiro Aoki; Takashi Watanabe; Dai Maruyama; Masahiro Yokoyama; Takatoshi Takubo; Hideaki Kagehara; Takafumi Matsushima
Journal:  Cancer Sci       Date:  2014-07-01       Impact factor: 6.716
  10 in total
  1 in total

Review 1.  Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2016-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.